Regio Biosciences

Regio Biosciences mainly focuses on targeted biotherapies, directly increasing plaque efflux of low-density lipoprotein cholesterol by enhancing Apo-A1 and high-quality functional HDL, reducing plaque burden and addressing associated CAD and PAD. The company is committed to solving multi-arterial bed atherosclerosis, offering new hope for patients with cardiovascular diseases CAD and PAD.